(Q45139118)

English

Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram

scientific article published in December 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 December 2017

Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram (English)

1 reference

Europe PubMed Central

9 December 2017

author name string

Per Allard

1

1 reference

Europe PubMed Central

9 December 2017

Lars Gram

2

1 reference

Europe PubMed Central

9 December 2017

Kristina Timdahl

3

1 reference

Europe PubMed Central

9 December 2017

Kirsten Behnke

4

1 reference

Europe PubMed Central

9 December 2017

Martin Hanson

5

1 reference

Europe PubMed Central

9 December 2017

Jesper Søgaard

6

1 reference

Europe PubMed Central

9 December 2017

language of work or name

0 references

publication date

1 December 2004

1 reference

Europe PubMed Central

9 December 2017

International Journal of Geriatric Psychiatry

1 reference

Europe PubMed Central

9 December 2017

19

1 reference

Europe PubMed Central

9 December 2017

1123-1130

1 reference

Europe PubMed Central

9 December 2017

12

1 reference

Europe PubMed Central

9 December 2017

Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

21 January 2018

Single-blind comparison of venlafaxine and nortriptyline in elderly major depression

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

21 January 2018

Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

21 January 2018

Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

21 January 2018

Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

21 January 2018

Depression and mortality in nursing homes

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

21 January 2018

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

21 January 2018

Long-term treatment of geropsychiatric depressed patients with venlafaxine

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

7 January 2021

based on heuristic

inferred from DOI database lookup

Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults.

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

7 January 2021

based on heuristic

inferred from DOI database lookup

Depression and coronary heart disease: a review for cardiologists.

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

7 January 2021

based on heuristic

inferred from DOI database lookup

An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients.

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

7 January 2021

based on heuristic

inferred from DOI database lookup

Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

7 January 2021

based on heuristic

inferred from DOI database lookup

Depression and 18-month prognosis after myocardial infarction.

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

7 January 2021

based on heuristic

inferred from DOI database lookup

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

7 January 2021

based on heuristic

inferred from DOI database lookup

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

7 January 2021

based on heuristic

inferred from DOI database lookup

Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

7 January 2021

based on heuristic

inferred from DOI database lookup

Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

7 January 2021

based on heuristic

inferred from DOI database lookup

Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders

1 reference

https://api.crossref.org/works/10.1002%2FGPS.1190

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/GPS.1190

1 reference

Europe PubMed Central

9 December 2017

1 reference

Europe PubMed Central

9 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45139118&oldid=2066780020"